ULTOMIRIS® Safety Profile1
MedDRA System Organ Class
Very common
(≥ 1/10)
Common
(≥ 1/100 to < 1/10)
Uncommon
(≥ 1/1,000 to < 1/100)
Gastrointestinal disorders
Diarrhoea, Nausea
Vomiting, Abdominal pain, Dyspepsia
General disorders and administration site conditions
Fatigue
Pyrexia, influenza like illness, Asthenia
Chills
Immune system disorders
Hypersensitivity, Anaphylactic reaction*
Infections and infestations
Upper respiratory tract infection, Nasopharyngitis
Meningococcal infection†, Gonococcal infection‡
Injury, poisoning and procedural complications
Infusion-related reaction
Musculoskeletal and connective tissue disorders
Arthralgia, Back pain, Myalgia, Muscle spasms
Nervous system disorders
Headache
Dizziness
Skin and subcutaneous tissue disorders
Urticaria*, Pruritus, Rash
* Estimated from post-marketing experience.
† Meningococcal infection includes preferred terms of meningococcal infection and meningococcal sepsis.
‡ Gonococcal infection includes disseminated gonococcal infection.